IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) Director Jakob Haldor Topsoe purchased 1,481 shares of the company’s stock in a transaction dated Friday, May 20th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $23,696.00. Following the transaction, the director now directly owns 73,462 shares in the company, valued at approximately $1,175,392. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of IGM Biosciences stock traded down $1.38 during trading on Tuesday, reaching $17.37. 610,658 shares of the company traded hands, compared to its average volume of 892,134. The firm has a market capitalization of $738.69 million, a PE ratio of -3.40 and a beta of -0.13. The company has a 50 day moving average price of $18.57 and a 200-day moving average price of $26.02. IGM Biosciences, Inc. has a 1-year low of $12.74 and a 1-year high of $99.44.
IGM Biosciences (NASDAQ:IGMS – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($1.50) EPS for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.08. During the same quarter in the prior year, the business posted ($0.79) EPS. As a group, equities research analysts forecast that IGM Biosciences, Inc. will post -6.01 earnings per share for the current year.
A number of brokerages have recently issued reports on IGMS. Zacks Investment Research downgraded shares of IGM Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 2nd. HC Wainwright dropped their price target on shares of IGM Biosciences from $59.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, May 17th. Wedbush dropped their price target on shares of IGM Biosciences from $67.00 to $58.00 in a research report on Thursday, March 31st. Morgan Stanley boosted their target price on shares of IGM Biosciences from $25.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 30th. Finally, Robert W. Baird dropped their target price on shares of IGM Biosciences from $65.00 to $46.00 and set an “outperform” rating on the stock in a research report on Monday, April 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, IGM Biosciences has a consensus rating of “Buy” and an average target price of $59.10.
About IGM Biosciences (Get Rating)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.